Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | SORT1 | Q99523 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | JMJD1C | Q15652 | 1/20 | 0.36 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1578942 | 0.83 | KDM4E (0.53) | ALDH1A1SORT1KDM4EKDM5AJMJD1C | |
| Ammonia Solution, Strong SCHEMBL27766041 | 0.81 | KDM4E (0.52) | ALDH1A1SORT1KDM4EKDM5AJMJD1C | |
| SCHEMBL27801110 | 0.81 | KDM4E (0.52) | ALDH1A1SORT1KDM4EKDM5AJMJD1C | |
| SCHEMBL14192611 | 0.81 | SORT1 (0.39) | ALDH1A1SORT1KDM4EKDM5AJMJD1C | |
| SCHEMBL2829062 | 0.81 | ADORA3 (0.41) | SORT1KDM4EKDM5AJMJD1CKDM3A | |
| SCHEMBL15188016 | 0.80 | CYP1A2 (0.38) | ALDH1A1SORT1KDM4EKDM5AJMJD1C | |
| Hydrochloric Acid SCHEMBL14759408 | 0.79 | ADORA3 (0.39) | SORT1KDM4EKDM5AJMJD1CKDM3A | |
| SCHEMBL1256533 | 0.78 | ALDH1A1 (0.47) | ALDH1A1KDM4EKDM5AJMJD1CKDM3A | |
| SCHEMBL3590598 | 0.78 | ALDH1A1 (0.47) | ALDH1A1KDM4EKDM5AJMJD1CKDM3A | |
| SCHEMBL3590602 | 0.78 | ALDH1A1 (0.47) | ALDH1A1KDM4EKDM5AJMJD1CKDM3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101494999-A | Method for using organic compound | GIVAUDAN SA (CH) | 2009-07-29 | — | — | CN | claimed |
| US-4232156-A | FLAVORS | FIRMENICH, S.A. (CH) | 1980-11-04 | — | — | US | claimed |
| US-4166869-A | Use of certain acyl-pyrimidines as flavouring agents | FIRMENICH, S.A. (CH) | 1979-09-04 | — | — | US | claimed |
| EP-4146220-B1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4672982-A1 | PROCESS FOR PREPARING A FLAVOR COMPOSITION | Firmenich SA (CH) | 2026-01-07 | — | — | EP | disclosed |
| US-20250388574-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC (US) | 2025-12-25 | — | — | US | disclosed |
| WO-2025235874-A1 | HETEROCYCLICS AS EGFR INHIBITORS | SCHRÖDINGER, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| US-12319691-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2025-06-03 | — | — | US | disclosed |
| US-12252489-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2025-03-18 | — | — | US | disclosed |
| CN-119111679-A | Gel candy capable of improving anoxia tolerance and preparation method thereof | 西北农林科技大学 | 2024-12-13 | — | — | CN | disclosed |
| WO-2024179905-A1 | PROCESS FOR PREPARING A FLAVOR COMPOSITION | FIRMENICH SA (CH) | 2024-09-06 | — | — | WO | disclosed |
| EP-2641901-A1 | Novel microbiocides | Syngenta Participations AG. (CH) | 2013-09-25 | — | — | EP | disclosed |
| US-8507485-B2 | Cyclic compound having pyrimidinylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-08-13 | — | — | US | disclosed |
| WO-2012038521-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-03-29 | — | — | WO | disclosed |
| US-20110124646-A1 | Novel cyclic compound having pyrimidinylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-05-26 | — | — | US | disclosed |
| US-20100248390-A1 | COMPOSITIONS AND METHODS FOR IDENTIFYING LIGANDS OF ODORANT RECEPTORS | DUKE UNIVERSITY (US) | 2010-09-30 | — | — | US | disclosed |
| CN-101494999-A | Method for using organic compound | GIVAUDAN SA (CH) | 2009-07-29 | — | — | CN | disclosed |
| US-20080015353-A1 | PROCESS FOR PRODUCTION OF 4-ACETYLPYRIMIDINES AND CRYSTALS THEREOF | AJINOMOTO CO., INC. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-4232156-A | FLAVORS | FIRMENICH, S.A. (CH) | 1980-11-04 | — | — | US | disclosed |
| US-4166869-A | Use of certain acyl-pyrimidines as flavouring agents | FIRMENICH, S.A. (CH) | 1979-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015353-A1 | PROCESS FOR PRODUCTION OF 4-ACETYLPYRIMIDINES AND CRYSTALS THEREOF | DPYD, UMPS, PNPO | ALDH1A1 352/4885SORT1 4454/4885KDM4E 200/4885 |
| US-12252489-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | ALDH1A1 2557/4885SORT1 386/4885KDM4E 3946/4885 |
| US-12319691-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | ALDH1A1 2654/4885SORT1 420/4885KDM4E 3817/4885 |
| US-20110124646-A1 | Novel cyclic compound having pyrimidinylalkylthio group | FLT1, VEGFA, FLT4 | ALDH1A1 185/4885SORT1 3671/4885KDM4E 3990/4885 |
| US-20250388574-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FCER2, HAVCR2 | ALDH1A1 2652/4885SORT1 702/4885KDM4E 4273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.